BTI:CA:CDX-biOasis Technologies Inc

EQUITY | Biotechnology | TSX Venture Exchange

Last Closing

USD 0.275

Change

-0.02 (-5.17)%

Market Cap

USD 0.04B

Volume

3.00K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

biOasis Technologies Inc is a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier and into the brain tissue. Its focus is to address unmet medical needs with its proprietary Transcend Platform.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-06-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

+0.12 (+5.83%)

USD 0.15B
ARCH:CA Arch Biopartners Inc

-0.17 (-7.17%)

USD 0.14B
MIR:CA MedMira Inc

+0.01 (+6.25%)

USD 0.06B
NRX:CA NurExone Biologic Inc.

-0.02 (-2.56%)

USD 0.04B
IBT:CA IBEX Technologies Inc

N/A

USD 0.03B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.03B
COV:CA Covalon Technologies Ltd.

N/A

USD 0.03B
SBM:CA Sirona Biochem Corp

-0.01 (-7.14%)

USD 0.02B
CZO:CA Ceapro

-0.01 (-2.08%)

USD 0.02B

ETFs Containing BTI:CA

HAZ 0.00 % 1.76 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -42.71% 23% F 14% F
Dividend Return N/A N/A N/A N/A F
Total Return -42.71% 23% F 14% F
Trailing 12 Months  
Capital Gain -61.81% 23% F 19% F
Dividend Return N/A N/A N/A N/A F
Total Return -61.81% 23% F 19% F
Trailing 5 Years  
Capital Gain -78.52% 19% F 15% F
Dividend Return N/A N/A N/A N/A F
Total Return -78.52% 19% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain -17.41% 11% F 11% F
Dividend Return -17.41% 11% F 11% F
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 30.48% 75% C 79% B-
Risk Adjusted Return -57.12% 14% F 12% F
Market Capitalization 0.04B 51% F 75% C

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -3.44 66% 62%
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio -1.10 42% 54%
Price/Free Cash Flow Ratio -4.58 48% 63%
Management Effectiveness  
Return on Equity -733.88% 3% 2%
Return on Invested Capital -907.43% 9% 2%
Return on Assets -220.24% 20% 13%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector